In the following video, Motley Fool health-care bureau chief Brenton Flynn discusses some diverging trends in the prices of pharmaceuticals. According to Express Scripts' (NASDAQ:ESRX) drug trend report, while traditional drug prices are down year over year, prices of specialty drugs have shot up almost 20%. These types of drug are typically more complicated to administer, difficult to discover or manufacture, and generally used for chronic or long-term conditions with few other options. Brenton tells investors why companies continue to shift its focus toward the lucrative specialty drug field.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Express Scripts Holding Company Broke Out in December
Express Scripts started to shake off the negative headwinds facing its industry last month.
3 Top Value Stocks to Buy in 2018
Express Scripts Holding Company, Horizon Pharma plc, and Sanofi plc are three cheap stocks worth considering in 2018.
Express Scripts (ESRX) Q3 2017 Earnings Conference Call Transcript
ESRX earnings call for the period ending September 30, 2017.